APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sterile Injectable CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sterile Injectable CDMO Market Outlook and Growth Opportunities 2026

30 January 2026214 pages

Choose your research edition.

Industry ResearchSterile Injectable CDMO Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Sterile Injectable CDMO Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Sterile Injectable CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sterile Injectable CDMO Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Sterile Injectable CDMO Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Sterile Injectable CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sterile Injectable CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sterile Injectable CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sterile Injectable CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sterile Injectable CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sterile Injectable CDMO market include Abbvie, Famar, Polfa Tarchomin, Pfizer, Quotient Sciences, Temad Co., Tianjin Hankang Pharmaceutical Biotechnology, Fareva and Sharp, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Sterile Injectable CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sterile Injectable CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sterile Injectable CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sterile Injectable CDMO market.

Sterile Injectable CDMO Segment by Company

Abbvie

Famar

Polfa Tarchomin

Pfizer

Quotient Sciences

Temad Co.

Tianjin Hankang Pharmaceutical Biotechnology

Fareva

Sharp

Astral SteriTech

Evonik

Aurigene Pharmaceutical Services

Prague Scientific

Ethypharm

TriRx Pharmaceutical Services

Biophrama Group

Gensenta Pharmaceuticals

BioTechnique

Mithra CDMo

S.C. Rompharm Company SRL

Flagship Biotech International Pvt. Ltd

Curida AS

BirgiMefar Group

Brooks Laboratories Limited

Sterile Injectable CDMO Segment by Type

Preclinical Manufacturing

Clinical Manufacturing

Commercial Manufacturing

Sterile Injectable CDMO Segment by Application

Pharmaceutical Company

Research Institute

Other

Sterile Injectable CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sterile Injectable CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sterile Injectable CDMO key companies, revenue, market share, and recent developments.

3. To split the Sterile Injectable CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sterile Injectable CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sterile Injectable CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Sterile Injectable CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sterile Injectable CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sterile Injectable CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sterile Injectable CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sterile Injectable CDMO industry.

Chapter 3: Detailed analysis of Sterile Injectable CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sterile Injectable CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sterile Injectable CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sterile Injectable CDMO Industry Trends Table 2. Sterile Injectable CDMO Industry Drivers Table 3. Sterile Injectable CDMO Industry Opportunities and Challenges Table 4. Sterile Injectable CDMO Industry Restraints Table 5. Global Sterile Injectable CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sterile Injectable CDMO Revenue Share by Company (2021-2026) Table 7. Global Sterile Injectable CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sterile Injectable CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Sterile Injectable CDMO Company, Product Type & Application Table 10. Global Sterile Injectable CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sterile Injectable CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Preclinical Manufacturing Table 15. Significant Companies of Clinical Manufacturing Table 16. Significant Companies of Commercial Manufacturing Table 17. Global Sterile Injectable CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Sterile Injectable CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Sterile Injectable CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Sterile Injectable CDMO Sales Value Share by Type (2021-2026) Table 21. Global Sterile Injectable CDMO Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pharmaceutical Company Table 23. Significant Companies of Research Institute Table 24. Significant Companies of Other Table 25. Global Sterile Injectable CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Sterile Injectable CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Sterile Injectable CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Sterile Injectable CDMO Sales Value Share by Application (2021-2026) Table 29. Global Sterile Injectable CDMO Sales Value Share by Application (2027-2032) Table 30. Global Sterile Injectable CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Sterile Injectable CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Sterile Injectable CDMO Sales Value Share by Region (2021-2026) Table 33. Global Sterile Injectable CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Sterile Injectable CDMO Sales Value Share by Region (2027-2032) Table 35. Global Sterile Injectable CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Sterile Injectable CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Sterile Injectable CDMO Sales Value Market Share by Country (2021-2026) Table 38. Global Sterile Injectable CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Sterile Injectable CDMO Sales Value Market Share by Country (2027-2032) Table 40. Abbvie Company Information Table 41. Abbvie Business Overview Table 42. Abbvie Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Abbvie Sterile Injectable CDMO Product Portfolio Table 44. Abbvie Recent Development Table 45. Famar Company Information Table 46. Famar Business Overview Table 47. Famar Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Famar Sterile Injectable CDMO Product Portfolio Table 49. Famar Recent Development Table 50. Polfa Tarchomin Company Information Table 51. Polfa Tarchomin Business Overview Table 52. Polfa Tarchomin Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Polfa Tarchomin Sterile Injectable CDMO Product Portfolio Table 54. Polfa Tarchomin Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer Sterile Injectable CDMO Product Portfolio Table 59. Pfizer Recent Development Table 60. Quotient Sciences Company Information Table 61. Quotient Sciences Business Overview Table 62. Quotient Sciences Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Quotient Sciences Sterile Injectable CDMO Product Portfolio Table 64. Quotient Sciences Recent Development Table 65. Temad Co. Company Information Table 66. Temad Co. Business Overview Table 67. Temad Co. Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Temad Co. Sterile Injectable CDMO Product Portfolio Table 69. Temad Co. Recent Development Table 70. Tianjin Hankang Pharmaceutical Biotechnology Company Information Table 71. Tianjin Hankang Pharmaceutical Biotechnology Business Overview Table 72. Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Product Portfolio Table 74. Tianjin Hankang Pharmaceutical Biotechnology Recent Development Table 75. Fareva Company Information Table 76. Fareva Business Overview Table 77. Fareva Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Fareva Sterile Injectable CDMO Product Portfolio Table 79. Fareva Recent Development Table 80. Sharp Company Information Table 81. Sharp Business Overview Table 82. Sharp Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sharp Sterile Injectable CDMO Product Portfolio Table 84. Sharp Recent Development Table 85. Astral SteriTech Company Information Table 86. Astral SteriTech Business Overview Table 87. Astral SteriTech Sterile Injectable CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Astral SteriTech Sterile Injectable CDMO Product Portfolio Table 89. Astral SteriTech Recent Development Table 90. Evonik Company Information Table 91. Evonik Business Overview Table 92. Evonik Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Evonik Sterile Injectable CDMO Product Portfolio Table 94. Evonik Recent Development Table 95. Aurigene Pharmaceutical Services Company Information Table 96. Aurigene Pharmaceutical Services Business Overview Table 97. Aurigene Pharmaceutical Services Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Aurigene Pharmaceutical Services Sterile Injectable CDMO Product Portfolio Table 99. Aurigene Pharmaceutical Services Recent Development Table 100. Prague Scientific Company Information Table 101. Prague Scientific Business Overview Table 102. Prague Scientific Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Prague Scientific Sterile Injectable CDMO Product Portfolio Table 104. Prague Scientific Recent Development Table 105. Ethypharm Company Information Table 106. Ethypharm Business Overview Table 107. Ethypharm Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Ethypharm Sterile Injectable CDMO Product Portfolio Table 109. Ethypharm Recent Development Table 110. TriRx Pharmaceutical Services Company Information Table 111. TriRx Pharmaceutical Services Business Overview Table 112. TriRx Pharmaceutical Services Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. TriRx Pharmaceutical Services Sterile Injectable CDMO Product Portfolio Table 114. TriRx Pharmaceutical Services Recent Development Table 115. Biophrama Group Company Information Table 116. Biophrama Group Business Overview Table 117. Biophrama Group Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Biophrama Group Sterile Injectable CDMO Product Portfolio Table 119. Biophrama Group Recent Development Table 120. Gensenta Pharmaceuticals Company Information Table 121. Gensenta Pharmaceuticals Business Overview Table 122. Gensenta Pharmaceuticals Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Gensenta Pharmaceuticals Sterile Injectable CDMO Product Portfolio Table 124. Gensenta Pharmaceuticals Recent Development Table 125. BioTechnique Company Information Table 126. BioTechnique Business Overview Table 127. BioTechnique Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. BioTechnique Sterile Injectable CDMO Product Portfolio Table 129. BioTechnique Recent Development Table 130. Mithra CDMo Company Information Table 131. Mithra CDMo Business Overview Table 132. Mithra CDMo Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Mithra CDMo Sterile Injectable CDMO Product Portfolio Table 134. Mithra CDMo Recent Development Table 135. S.C. Rompharm Company SRL Company Information Table 136. S.C. Rompharm Company SRL Business Overview Table 137. S.C. Rompharm Company SRL Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. S.C. Rompharm Company SRL Sterile Injectable CDMO Product Portfolio Table 139. S.C. Rompharm Company SRL Recent Development Table 140. Flagship Biotech International Pvt. Ltd Company Information Table 141. Flagship Biotech International Pvt. Ltd Business Overview Table 142. Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Product Portfolio Table 144. Flagship Biotech International Pvt. Ltd Recent Development Table 145. Curida AS Company Information Table 146. Curida AS Business Overview Table 147. Curida AS Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 148. Curida AS Sterile Injectable CDMO Product Portfolio Table 149. Curida AS Recent Development Table 150. BirgiMefar Group Company Information Table 151. BirgiMefar Group Business Overview Table 152. BirgiMefar Group Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 153. BirgiMefar Group Sterile Injectable CDMO Product Portfolio Table 154. BirgiMefar Group Recent Development Table 155. Brooks Laboratories Limited Company Information Table 156. Brooks Laboratories Limited Business Overview Table 157. Brooks Laboratories Limited Sterile Injectable CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 158. Brooks Laboratories Limited Sterile Injectable CDMO Product Portfolio Table 159. Brooks Laboratories Limited Recent Development Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Sterile Injectable CDMO Product Image Figure 2. Global Sterile Injectable CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sterile Injectable CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Sterile Injectable CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Preclinical Manufacturing Image Figure 8. Clinical Manufacturing Image Figure 9. Commercial Manufacturing Image Figure 10. Global Sterile Injectable CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sterile Injectable CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Sterile Injectable CDMO Sales Value Share by Type (2021-2032) Figure 13. Pharmaceutical Company Image Figure 14. Research Institute Image Figure 15. Other Image Figure 16. Global Sterile Injectable CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Sterile Injectable CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Sterile Injectable CDMO Sales Value Share by Application (2021-2032) Figure 19. Global Sterile Injectable CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Sterile Injectable CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Sterile Injectable CDMO Sales Value (2021-2032) & (US$ Million) Figure 22. North America Sterile Injectable CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Sterile Injectable CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Sterile Injectable CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Sterile Injectable CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Sterile Injectable CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Sterile Injectable CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. South America Sterile Injectable CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Sterile Injectable CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Sterile Injectable CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Sterile Injectable CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Preclinical Manufacturing
  • Clinical Manufacturing
  • Commercial Manufacturing
Applications
  • Pharmaceutical Company
  • Research Institute
  • Other
Companies covered
  • Abbvie
  • Famar
  • Polfa Tarchomin
  • Pfizer
  • Quotient Sciences
  • Temad Co.
  • Tianjin Hankang Pharmaceutical Biotechnology
  • Fareva
  • Sharp
  • Astral SteriTech
  • Evonik
  • Aurigene Pharmaceutical Services
  • Prague Scientific
  • Ethypharm
  • TriRx Pharmaceutical Services
  • Biophrama Group
  • Gensenta Pharmaceuticals
  • BioTechnique
  • Mithra CDMo
  • S.C. Rompharm Company SRL
  • Flagship Biotech International Pvt. Ltd
  • Curida AS
  • BirgiMefar Group
  • Brooks Laboratories Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sterile Injectable CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sterile Injectable CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sterile Injectable CDMO Market Dynamics
  1. 2.1 Sterile Injectable CDMO Industry Trends
  2. 2.2 Sterile Injectable CDMO Industry Drivers
  3. 2.3 Sterile Injectable CDMO Industry Opportunities and Challenges
  4. 2.4 Sterile Injectable CDMO Industry Restraints
3 Sterile Injectable CDMO Market by Company
  1. 3.1 Global Sterile Injectable CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Sterile Injectable CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Sterile Injectable CDMO Company Ranking (2024-2026)
  4. 3.4 Global Sterile Injectable CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Sterile Injectable CDMO Company Product Type and Application
  6. 3.6 Global Sterile Injectable CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sterile Injectable CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sterile Injectable CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sterile Injectable CDMO Market by Type
  1. 4.1 Sterile Injectable CDMO Type Introduction
  2. 4.1.1 Preclinical Manufacturing
  3. 4.1.2 Clinical Manufacturing
  4. 4.1.3 Commercial Manufacturing
  5. 4.2 Global Sterile Injectable CDMO Sales Value by Type
  6. 4.2.1 Global Sterile Injectable CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Sterile Injectable CDMO Sales Value by Type (2021-2032)
  8. 4.2.3 Global Sterile Injectable CDMO Sales Value Share by Type (2021-2032)
5 Sterile Injectable CDMO Market by Application
  1. 5.1 Sterile Injectable CDMO Application Introduction
  2. 5.1.1 Pharmaceutical Company
  3. 5.1.2 Research Institute
  4. 5.1.3 Other
  5. 5.2 Global Sterile Injectable CDMO Sales Value by Application
  6. 5.2.1 Global Sterile Injectable CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sterile Injectable CDMO Sales Value by Application (2021-2032)
  8. 5.2.3 Global Sterile Injectable CDMO Sales Value Share by Application (2021-2032)
6 Sterile Injectable CDMO Regional Value Analysis
  1. 6.1 Global Sterile Injectable CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sterile Injectable CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sterile Injectable CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sterile Injectable CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sterile Injectable CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Sterile Injectable CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sterile Injectable CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Sterile Injectable CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sterile Injectable CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sterile Injectable CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sterile Injectable CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Sterile Injectable CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sterile Injectable CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sterile Injectable CDMO Sales Value Share by Country, 2025 VS 2032
7 Sterile Injectable CDMO Country-level Value Analysis
  1. 7.1 Global Sterile Injectable CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sterile Injectable CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sterile Injectable CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sterile Injectable CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sterile Injectable CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sterile Injectable CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sterile Injectable CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbvie
  2. 8.1.1 Abbvie Company Information
  3. 8.1.2 Abbvie Business Overview
  4. 8.1.3 Abbvie Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbvie Sterile Injectable CDMO Product Portfolio
  6. 8.1.5 Abbvie Recent Developments
  7. 8.2 Famar
  8. 8.2.1 Famar Company Information
  9. 8.2.2 Famar Business Overview
  10. 8.2.3 Famar Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Famar Sterile Injectable CDMO Product Portfolio
  12. 8.2.5 Famar Recent Developments
  13. 8.3 Polfa Tarchomin
  14. 8.3.1 Polfa Tarchomin Company Information
  15. 8.3.2 Polfa Tarchomin Business Overview
  16. 8.3.3 Polfa Tarchomin Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Polfa Tarchomin Sterile Injectable CDMO Product Portfolio
  18. 8.3.5 Polfa Tarchomin Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Sterile Injectable CDMO Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Quotient Sciences
  26. 8.5.1 Quotient Sciences Company Information
  27. 8.5.2 Quotient Sciences Business Overview
  28. 8.5.3 Quotient Sciences Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Quotient Sciences Sterile Injectable CDMO Product Portfolio
  30. 8.5.5 Quotient Sciences Recent Developments
  31. 8.6 Temad Co.
  32. 8.6.1 Temad Co. Company Information
  33. 8.6.2 Temad Co. Business Overview
  34. 8.6.3 Temad Co. Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Temad Co. Sterile Injectable CDMO Product Portfolio
  36. 8.6.5 Temad Co. Recent Developments
  37. 8.7 Tianjin Hankang Pharmaceutical Biotechnology
  38. 8.7.1 Tianjin Hankang Pharmaceutical Biotechnology Company Information
  39. 8.7.2 Tianjin Hankang Pharmaceutical Biotechnology Business Overview
  40. 8.7.3 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Tianjin Hankang Pharmaceutical Biotechnology Sterile Injectable CDMO Product Portfolio
  42. 8.7.5 Tianjin Hankang Pharmaceutical Biotechnology Recent Developments
  43. 8.8 Fareva
  44. 8.8.1 Fareva Company Information
  45. 8.8.2 Fareva Business Overview
  46. 8.8.3 Fareva Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fareva Sterile Injectable CDMO Product Portfolio
  48. 8.8.5 Fareva Recent Developments
  49. 8.9 Sharp
  50. 8.9.1 Sharp Company Information
  51. 8.9.2 Sharp Business Overview
  52. 8.9.3 Sharp Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sharp Sterile Injectable CDMO Product Portfolio
  54. 8.9.5 Sharp Recent Developments
  55. 8.10 Astral SteriTech
  56. 8.10.1 Astral SteriTech Company Information
  57. 8.10.2 Astral SteriTech Business Overview
  58. 8.10.3 Astral SteriTech Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Astral SteriTech Sterile Injectable CDMO Product Portfolio
  60. 8.10.5 Astral SteriTech Recent Developments
  61. 8.11 Evonik
  62. 8.11.1 Evonik Company Information
  63. 8.11.2 Evonik Business Overview
  64. 8.11.3 Evonik Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Evonik Sterile Injectable CDMO Product Portfolio
  66. 8.11.5 Evonik Recent Developments
  67. 8.12 Aurigene Pharmaceutical Services
  68. 8.12.1 Aurigene Pharmaceutical Services Company Information
  69. 8.12.2 Aurigene Pharmaceutical Services Business Overview
  70. 8.12.3 Aurigene Pharmaceutical Services Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aurigene Pharmaceutical Services Sterile Injectable CDMO Product Portfolio
  72. 8.12.5 Aurigene Pharmaceutical Services Recent Developments
  73. 8.13 Prague Scientific
  74. 8.13.1 Prague Scientific Company Information
  75. 8.13.2 Prague Scientific Business Overview
  76. 8.13.3 Prague Scientific Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Prague Scientific Sterile Injectable CDMO Product Portfolio
  78. 8.13.5 Prague Scientific Recent Developments
  79. 8.14 Ethypharm
  80. 8.14.1 Ethypharm Company Information
  81. 8.14.2 Ethypharm Business Overview
  82. 8.14.3 Ethypharm Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ethypharm Sterile Injectable CDMO Product Portfolio
  84. 8.14.5 Ethypharm Recent Developments
  85. 8.15 TriRx Pharmaceutical Services
  86. 8.15.1 TriRx Pharmaceutical Services Company Information
  87. 8.15.2 TriRx Pharmaceutical Services Business Overview
  88. 8.15.3 TriRx Pharmaceutical Services Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 TriRx Pharmaceutical Services Sterile Injectable CDMO Product Portfolio
  90. 8.15.5 TriRx Pharmaceutical Services Recent Developments
  91. 8.16 Biophrama Group
  92. 8.16.1 Biophrama Group Company Information
  93. 8.16.2 Biophrama Group Business Overview
  94. 8.16.3 Biophrama Group Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biophrama Group Sterile Injectable CDMO Product Portfolio
  96. 8.16.5 Biophrama Group Recent Developments
  97. 8.17 Gensenta Pharmaceuticals
  98. 8.17.1 Gensenta Pharmaceuticals Company Information
  99. 8.17.2 Gensenta Pharmaceuticals Business Overview
  100. 8.17.3 Gensenta Pharmaceuticals Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Gensenta Pharmaceuticals Sterile Injectable CDMO Product Portfolio
  102. 8.17.5 Gensenta Pharmaceuticals Recent Developments
  103. 8.18 BioTechnique
  104. 8.18.1 BioTechnique Company Information
  105. 8.18.2 BioTechnique Business Overview
  106. 8.18.3 BioTechnique Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  107. 8.18.4 BioTechnique Sterile Injectable CDMO Product Portfolio
  108. 8.18.5 BioTechnique Recent Developments
  109. 8.19 Mithra CDMo
  110. 8.19.1 Mithra CDMo Company Information
  111. 8.19.2 Mithra CDMo Business Overview
  112. 8.19.3 Mithra CDMo Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Mithra CDMo Sterile Injectable CDMO Product Portfolio
  114. 8.19.5 Mithra CDMo Recent Developments
  115. 8.20 S.C. Rompharm Company SRL
  116. 8.20.1 S.C. Rompharm Company SRL Company Information
  117. 8.20.2 S.C. Rompharm Company SRL Business Overview
  118. 8.20.3 S.C. Rompharm Company SRL Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  119. 8.20.4 S.C. Rompharm Company SRL Sterile Injectable CDMO Product Portfolio
  120. 8.20.5 S.C. Rompharm Company SRL Recent Developments
  121. 8.21 Flagship Biotech International Pvt. Ltd
  122. 8.21.1 Flagship Biotech International Pvt. Ltd Company Information
  123. 8.21.2 Flagship Biotech International Pvt. Ltd Business Overview
  124. 8.21.3 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Flagship Biotech International Pvt. Ltd Sterile Injectable CDMO Product Portfolio
  126. 8.21.5 Flagship Biotech International Pvt. Ltd Recent Developments
  127. 8.22 Curida AS
  128. 8.22.1 Curida AS Company Information
  129. 8.22.2 Curida AS Business Overview
  130. 8.22.3 Curida AS Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Curida AS Sterile Injectable CDMO Product Portfolio
  132. 8.22.5 Curida AS Recent Developments
  133. 8.23 BirgiMefar Group
  134. 8.23.1 BirgiMefar Group Company Information
  135. 8.23.2 BirgiMefar Group Business Overview
  136. 8.23.3 BirgiMefar Group Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  137. 8.23.4 BirgiMefar Group Sterile Injectable CDMO Product Portfolio
  138. 8.23.5 BirgiMefar Group Recent Developments
  139. 8.24 Brooks Laboratories Limited
  140. 8.24.1 Brooks Laboratories Limited Company Information
  141. 8.24.2 Brooks Laboratories Limited Business Overview
  142. 8.24.3 Brooks Laboratories Limited Sterile Injectable CDMO Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Brooks Laboratories Limited Sterile Injectable CDMO Product Portfolio
  144. 8.24.5 Brooks Laboratories Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst